

1. Use of An antibody, or antigen binding fragment thereof, which is an inhibitor of signalling through IL-13R α 1, by binding the said receptor or a pharmaceutical composition comprising the same, in the manufacture of a medicament for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) in a highly allergic patient where the baseline IgE levels have been established and are at a level of at least 10,000 KU/L +/- 2,000, wherein the antibody or antigen binding fragment thereof comprises a VH domain comprising an amino acid sequence as set forth in SEQ ID NO: 51 and a VL domain comprising an amino acid sequence as set forth in SEQ ID NO: 53.
2. ~~An antibody, antigen binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to claim 1, wherein the baseline IgE levels are in the range 10,000 +/- 2,000 to 30,000 +/- 6,000 KU/L.
3. ~~An antibody, antigen binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to claim 1 or 2, wherein the treatment reduces the IgE levels by at least 15% from baseline.
4. ~~An antibody, binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to claim 3, wherein the treatment reduces the IgE levels by at least 20% from the baseline.
5. ~~An antibody, binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to claim 3 or 4, wherein the treatment reduces the IgE levels by at least 30% from baseline, for example reduces said levels 30 to 40%, such as 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40% from baseline.
6. ~~An antibody, binding fragment or a pharmaceutical composition comprising same for u~~Use according to any one of claims 3 to 5, wherein the reduction is observed by about day 15, by about day 29, or by about day 57.
7. ~~An antibody or binding fragment thereof or a pharmaceutical composition comprising same for use according to any one of claims 3 to 6, wherein the reduction is observed by about day 29.~~
8. ~~An antibody, binding fragment thereof or a pharmaceutical composition comprising same for use according to any one of claims 3 to 7, wherein the reduction is observed by about day 57.~~
9. ~~7. An antibody, binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to 8, wherein said antibody or binding fragment is administered by parenterally, for example in a treatment cycle comprising a dose in the range 200mg to 600mg.
10. ~~8. An antibody, binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to 9, wherein following the treatment cycle or cycles and disease modification, maintenance therapy is administered, for example the same dose administered less frequently (for example monthly), or a lower dose (such as 200mg) administered the same frequency or less frequently (such as about two weekly, about three weekly, or about four weekly).

~~11.9. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for use according to any one of claims 1 to 108, wherein said antibody or binding fragment thereof is administered approximately weekly, (in particular a single treatment cycle, especially 8 weeks).~~

- ~~12.10. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~108~~, wherein said antibody or binding fragment thereof is administered once approximately every two weeks, (in particular a single treatment cycle, especially 8 weeks).
- ~~13.11. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~108~~, wherein said antibody or binding fragment thereof is administered once approximately every three weeks, (in particular a single treatment cycle, especially 8 weeks).
- ~~14.12. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~108~~, wherein the antibody or binding fragment thereof is administered once approximately every four weeks (for example monthly), (in particular a single treatment cycle, especially 8 weeks).
- ~~15.13. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~1412~~, wherein a loading dose in the range 400 to 900mg, for example 400, 500, 600, 700, 800 or 900mg is employed before administration of the treatment cycle.
- ~~14. Use according to claim 13, wherein the loading dose is 600 mg.~~
- ~~16.15. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~1412~~, wherein the treatment does not comprise a loading dose.
- ~~17.16. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for use thereof~~Use according to any one of claims 1 to ~~1615~~, wherein the dose is 200mg.
- ~~18.17. An antibody, binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~1615~~, wherein the dose is in the range 350 to 450mg, such as 400mg.
- ~~19.18. An antibody, binding fragment thereof or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~1615~~, wherein the dose is 600mg.
- ~~20.19. An antibody or binding fragment for u~~Use according to any one claims 1 to ~~2318~~, wherein the treatment cycles comprises, a first dose at 600mg, followed by three weekly doses of 400mg, for example wherein the treatment cycle is repeated twice i.e. two treatment cycles lasting 8 weeks, in particular day 1 600mg, approximately day 8 400mg, approximately day 15 400mg, approximately day 22 400mg, approximately day 29 600mg, approximately day 36 400mg, approximately day 43 400mg, and approximately day 50 400mg are administered.
- ~~21.20. An antibody, antigen binding fragment or a pharmaceutical composition comprising same for u~~Use according to any one of claims 1 to ~~2019~~, wherein disease modification, occurs by day 4, wherein day 1 is the first administration of the antibody or binding fragment thereof, for example wherein disease modification is assessed by a reduction in EASI score.